{"id":690460,"date":"2024-03-06T09:24:01","date_gmt":"2024-03-06T09:24:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=690460"},"modified":"2024-03-06T09:24:01","modified_gmt":"2024-03-06T09:24:01","slug":"seasonal-influenza-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-cidara-moderna-sab-therapeutics-sinovac-biotech-novartis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/seasonal-influenza-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-cidara-moderna-sab-therapeutics-sinovac-biotech-novartis_690460.html","title":{"rendered":"Seasonal Influenza Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1709640162.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Seasonal Influenza Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis\" src=\"https:\/\/www.abnewswire.com\/uploads\/1709640162.jpeg\" alt=\"Seasonal Influenza Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cSeasonal Influenza Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Seasonal Influenza, historical and forecasted epidemiology as well as the Seasonal Influenza market trends in the 7MM.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s<strong> &ldquo;Seasonal Influenza Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Seasonal Influenza, historical and forecasted epidemiology as well as the Seasonal Influenza market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Seasonal Influenza market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/seasonal-influenza-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Seasonal Influenza Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Seasonal Influenza Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Seasonal Influenza market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period (2019-2032)<\/li>\n<li>Only <strong>49.2%<\/strong> of people aged 6 months and older who participated in the National Health Interview Survey (NHIS) reported having had a seasonal influenza vaccination for the flu season 2017&ndash;2018. Additionally, the NHIS indicated that their goal is to have 70% of people immunized against seasonal flu by the year 2030<\/li>\n<li>Acute pneumonia is a diagnosis made in about <strong>30&ndash;40%<\/strong> of hospitalized individuals with laboratory-confirmed influenza. These individuals who get pneumonia are more likely to be less than five years old, older than 65, Caucasian, nursing home residents, have a history of smoking and chronic lung or heart illness, and be immunocompromised<\/li>\n<li><strong>Key Seasonal Influenza Companies:<\/strong> Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis, and others<\/li>\n<li><strong>Key Seasonal Influenza Therapies:<\/strong> CD388, mRNA-1010, SAB-176, Quadrivalent influenza vaccine, TIVf, and others<\/li>\n<li>The Seasonal Influenza epidemiology based on type-specific cases analyzed that More patients of Influenza type-A were found compared to type-B<\/li>\n<li>The Seasonal Influenza market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Seasonal Influenza pipeline products will significantly revolutionize the Seasonal Influenza market dynamics.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Seasonal Influenza Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">The World Health Organization (WHO) describes seasonal influenza as an acute respiratory infection brought on by influenza viruses that are spread throughout the globe.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Seasonal Influenza Market Report&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/seasonal-influenza-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/seasonal-influenza-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Seasonal Influenza Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Seasonal Influenza Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Seasonal Influenza market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Seasonal Influenza<\/li>\n<li>Prevalent Cases of Seasonal Influenza by severity<\/li>\n<li>Gender-specific Prevalence of Seasonal Influenza<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Seasonal Influenza<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Seasonal Influenza epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/seasonal-influenza-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Seasonal Influenza Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Seasonal Influenza Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Seasonal Influenza market or expected to get launched during the study period. The analysis covers Seasonal Influenza market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Seasonal Influenza Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Seasonal Influenza Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>CD388:<\/strong> Cidara<\/li>\n<li><strong>mRNA-1010:<\/strong> Moderna<\/li>\n<li><strong>SAB-176:<\/strong> SAB Therapeutics<\/li>\n<li><strong>Quadrivalent influenza vaccine:<\/strong> Sinovac Biotech<\/li>\n<li><strong>TIV:<\/strong> Novartis<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Seasonal Influenza market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/seasonal-influenza-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Seasonal Influenza Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Seasonal Influenza Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li>Key Seasonal Influenza Companies: Cidara, Moderna, SAB Therapeutics, Sinovac Biotech, Novartis, and others<\/li>\n<li>Key Seasonal Influenza Therapies: CD388, mRNA-1010, SAB-176, Quadrivalent influenza vaccine, TIVf, and others<\/li>\n<li>Seasonal Influenza Therapeutic Assessment: Seasonal Influenza current marketed and Seasonal Influenza emerging therapies<\/li>\n<li>Seasonal Influenza Market Dynamics: Seasonal Influenza market drivers and Seasonal Influenza market barriers&nbsp;<\/li>\n<li>Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Seasonal Influenza Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Seasonal Influenza Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Seasonal Influenza companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/seasonal-influenza-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Seasonal Influenza Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Seasonal Influenza Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Seasonal Influenza<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Seasonal Influenza<\/p>\n<p style=\"text-align: justify;\">4. Seasonal Influenza Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Seasonal Influenza Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Seasonal Influenza Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Seasonal Influenza Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Seasonal Influenza&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Seasonal Influenza Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Seasonal Influenza Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Seasonal Influenza Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Seasonal Influenza Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Seasonal Influenza Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Seasonal Influenza Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Seasonal Influenza Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Seasonal Influenza Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Seasonal Influenza Appendix<\/p>\n<p style=\"text-align: justify;\">18. Seasonal Influenza Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=seasonal-influenza-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-cidara-moderna-sab-therapeutics-sinovac-biotech-novartis\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=seasonal-influenza-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-cidara-moderna-sab-therapeutics-sinovac-biotech-novartis\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201cSeasonal Influenza Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Seasonal Influenza, historical and forecasted epidemiology as well as the Seasonal Influenza market trends in the 7MM. DelveInsight&rsquo;s &ldquo;Seasonal Influenza Market Insights, Epidemiology, and Market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/seasonal-influenza-market-report-2032-epidemiology-data-pipeline-therapies-latest-fda-ema-pdma-approvals-by-delveinsight-cidara-moderna-sab-therapeutics-sinovac-biotech-novartis_690460.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-690460","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/690460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=690460"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/690460\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=690460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=690460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=690460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}